Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

NCT06337084 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult
Bladder Cancer
Urothelial Carcinoma
Triple-negative Breast Cancer
Lung Cancer
Colorectal Cancer
Gastric Cancer
Ovarian Cancer
Pancreatic Cancer

Interventions

DRUG: MNPR-101-DFO*-89Zr
DIAGNOSTIC_TEST: PET/CT Diagnostic Imaging

Sponsor

Monopar Therapeutics